Evolent Health (NYSE:EVH) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Evolent Health (NYSE:EVH) announced its earnings results on Thursday. The technology company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.05), FiscalAI reports. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The business had revenue of $479.53 million during the quarter, compared to analyst estimates of $473.74 million. During the same period in the previous year, the firm earned ($0.27) earnings per share. The firm’s revenue was down 22.8% compared to the same quarter last year. Evolent Health updated its Q4 2025 guidance to EPS.

Evolent Health Trading Down 17.3%

Shares of NYSE:EVH traded down $1.04 during trading on Friday, hitting $4.97. 8,699,049 shares of the company’s stock were exchanged, compared to its average volume of 2,714,930. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. The firm has a market cap of $583.43 million, a P/E ratio of -3.08 and a beta of 0.58. The firm has a 50-day moving average price of $8.16 and a two-hundred day moving average price of $9.04. Evolent Health has a 1-year low of $4.92 and a 1-year high of $15.56.

Institutional Trading of Evolent Health

A number of institutional investors have recently bought and sold shares of EVH. Durable Capital Partners LP bought a new stake in shares of Evolent Health during the 2nd quarter valued at $72,326,000. 8 Knots Management LLC bought a new stake in Evolent Health in the second quarter valued at about $32,802,000. Goldman Sachs Group Inc. increased its holdings in Evolent Health by 162.2% in the first quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company’s stock valued at $26,861,000 after purchasing an additional 1,754,520 shares during the last quarter. Holocene Advisors LP acquired a new position in Evolent Health in the second quarter valued at about $5,945,000. Finally, Hudson Bay Capital Management LP boosted its holdings in Evolent Health by 92.2% during the second quarter. Hudson Bay Capital Management LP now owns 760,211 shares of the technology company’s stock worth $8,560,000 after buying an additional 364,664 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have commented on EVH. Zacks Research lowered Evolent Health from a “hold” rating to a “strong sell” rating in a research note on Friday, October 10th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $16.00 price target on shares of Evolent Health in a report on Tuesday, September 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolent Health in a research report on Wednesday, October 8th. BTIG Research lowered their price objective on shares of Evolent Health from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Friday. Finally, Truist Financial increased their price target on shares of Evolent Health from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, July 17th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Evolent Health has a consensus rating of “Moderate Buy” and a consensus target price of $15.54.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.